Jaen Juan C. 4
4 · Arcus Biosciences, Inc. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
Arcus Biosciences (RCUS) President Juan Jaen Sells Shares
What Happened
- Juan C. Jaen, President of Arcus Biosciences (RCUS), sold a total of 31,431 shares in open-market transactions on June 22–24, 2026, realizing about $877,501. The trades were reported as sales (code S) and were effected under a pre-established Rule 10b5-1 trading plan adopted February 27, 2026. These are dispositions (routine sales), not purchases.
Key Details
- Transactions reported:
- 2026-06-22: 9,236 shares at a weighted avg $27.03 — proceeds $249,661 (prices ranged $27.00–$27.14) (F2).
- 2026-06-23: 14,067 shares at a weighted avg $27.69 — proceeds $389,480 (prices ranged $27.01–$28.00) (F3).
- 2026-06-23: 1,697 shares at a weighted avg $28.06 — proceeds $47,620 (prices ranged $28.0050–$28.1550) (F4).
- 2026-06-24: 6,431 shares at a weighted avg $29.66 — proceeds $190,740 (prices ranged $29.50–$29.8050) (F5).
- Total shares sold: 31,431; total reported proceeds: ~$877,501.
- Shares owned after transaction: not specified in the summary provided here — consult the full Form 4 for the reporting person’s total beneficial ownership (footnotes note inclusion of unvested RSUs and 1,279 ESPP shares) (F6, F7).
- Notable footnotes: F1 confirms the trades were made under a 10b5-1 plan (adopted Feb 27, 2026). F2–F5 explain each weighted-average price represents multiple executions within stated price ranges. F6/F7 describe components of reported holdings (unvested RSUs; 1,279 ESPP shares).
- Filing timeliness: Reported period of transactions was June 22, 2026; Form 4 was filed June 24, 2026 (appears timely).
Context
- Sales executed under a 10b5-1 plan are pre-scheduled transactions that allow insiders to sell shares according to a plan established when they are not in possession of material nonpublic information; such sales are often routine and do not by themselves indicate management sentiment.
- For retail investors, purchases generally carry more signal value than routine, pre-planned sales. This filing documents sales only — no purchases, exercises, or awards were reported in this Form 4.
Insider Transaction Report
Form 4
Jaen Juan C.
President
Transactions
- Sale
Common Stock
[F1][F2]2026-06-22$27.03/sh−9,236$249,661→ 913,004 total(indirect: By Trust) - Sale
Common Stock
[F1][F3]2026-06-23$27.69/sh−14,067$389,480→ 898,937 total(indirect: By Trust) - Sale
Common Stock
[F1][F4]2026-06-23$28.06/sh−1,697$47,620→ 897,240 total(indirect: By Trust) - Sale
Common Stock
[F1][F5]2026-06-24$29.66/sh−6,431$190,740→ 890,809 total(indirect: By Trust)
Holdings
- 378,291
Common Stock
[F6][F7]
Footnotes (7)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.01 to $28.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.0050 to $28.1550, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $29.8050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]Includes the unvested portion of the Reporting Person's RSU grants.
- [F7]Includes 1,279 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.
Signature
/s/ Carolyn Tang, Attorney-in-Fact|2026-06-24